Intellectual property related to the Australian Life Sciences sector

Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (29 September 2017)

The World Intellectual Property Organisation publishes new PCT patent applications every Thursday. Australian applicants generally have 12 or 13 healthcare and biotech-related patent applications published each month while New Zealand applicants have two or three a month.

Australian applications

Here are the 158 PCT patent applications relevant to Australia's Life Sciences sector that published in 2014, for a publication rate of 3.0 applications per week:

WO/2014/205516, Method of treating intracellular infection, Walter and Eliza Hall Institute of Medical Research, 31 December 2014
WO/2014/205511, Methods and compositions for modulating cancer stem cells, University of Canberra, 31 December 2014
WO/2014/205501, Il-21 binding proteins and uses thereof, Monash University, 31 December 2014
WO/2014/205491, Biological molecules and methods of use, Monash University, 31 December 2014
WO/2014/201525, Immunotherapy composition and use thereof, Ondek, 24 December 2014
WO/2014/201499, Johnson grass allergenic pollen proteins, encoding nucleic acids and methods of use, Queensland University of Technology, 24 December 2014
WO/2014/201492, Methods for the treatment of bladder cancer, Viralytics, 24 December 2014
WO/2014/197940, One step assembly of metal-polyphenol complexes for versatile film and particle engineering, University of Melbourne, 18 December 2014
WO/2014/197938, Combination therapy, Antisense Therapeutics, 18 December 2014
WO/2014/197937, Methods for detecting prostate cancer, University of South Australia, 18 December 2014
WO/2014/197934, Renal progenitor cells, University of Queensland, 18 December 2014
WO/2014/194364, Method of preventing or treating Bronchopulmonary Dysplasia (BPD) and Pulmonary Arterial Hypertension (PAH), Monash University, 11 December 2014
WO/2014/194362, Process for preparing Apolipoprotein A-I (APO A-I), CSL Ltd, 11 December 2014
WO/2014/190398, Inhibition of amyloid fibril formation, University of Melbourne, 4 December 2014
WO/2014/186843, Targeted delivery of drugs to the myometrium, Newcastle Innovation, 27 November 2014
WO/2014/186842, Antibodies and uses thereof, Monash University, 27 November 2014
WO/2014/186824, Treatment of neurological and other disorders, Palmaya, 27 November 2014
WO/2014/183168, Inhibitory propeptides, Oral Health Australia, 20 November 2014
WO/2014/183164, Dihydropyrrolones and their use as antimicrobial agents, Naresh Kumar, 20 November 2014
WO/2014/183147, Apricitabine and NRTI combination therapy, Avexa, 20 November 2014
WO/2014/180943, MCL-1 as critical regulator of Foxp3+ regulatory T cell survival, and use thereof to treat severe immune disorders, VIB (Belgium) with Katholieke Universiteit Leuven (Belgium) and Walter and Eliza Hall Institute of Medical Research, 13 November 2014
WO/2014/179845, Niacin formulation, Zeenar Enterprises, 13 November 2014
WO/2014/179843, Gluten enrichment of foods for Irritable Bowel Syndrome sufferers, Kerith Duncanson, 13 November 2014
WO/2014/179834, Compositions and methods for the treatment of tinnitus, Cell-Innovations, 13 November 2014
WO/2014/179831, Dosage projectile for remotely treating an animal, Smartvet, 13 November 2014
WO/2014/176636, Compounds and methods of treating infections, Neoculi, 6 November 2014
WO/2014/176634, Methods for treating bacterial infections, Neoculi, 6 November 2014
WO/2014/176632, Compositions and methods for treating microbiota-related psychotropic conditions and diseases, Thomas Borody, 6 November 2014
WO/2014/176394, Vitamin D receptor/SMAD genomic circuit gates fibrotic response, Salk Institute for Biological Studies (US) with University of Sydney, 30 October 2014
WO/2014/173873, Complex, CSL Ltd, 30 October 2014
WO/2014/172758, Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same, Terragen, 30 October 2014
WO/2014/172456, Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, Mayne Pharma with Hedgepath Pharmaceuticals (US), 23 October 2014
WO/2014/169356, Methods and compositions for wound healing, Qbiotics, 23 October 2014
WO/2014/169355, Method of viral inhibition, Monash University, 23 October 2014
WO/2014/169344, Methods and compositions for the treatment and/or prophylaxis of Clostridium Difficile associated disease, Immuron, 23 October 2014
WO/2014/165923, Composition for controlled delivery of bioactive agents, Commonwealth Scientific and Industrial Research Organisation, 16 October 2014
WO/2014/165916, Methods and compositions for inducing an immune response, Adelaide Research & Innovation, 16 October 2014
WO/2014/162303, Use of a dietary fibre supplement in a food formulation, Gratuk Technologies, 9 October 2014
WO/2014/161046, Methods of treating diseases characterized by excessive WNT signalling, Walter and Eliza Hall Institute of Medical Research, 9 October 2014
WO/2014/161037, Antibodies against human RYK and uses therefor, Peter MacCallum Cancer Institute, 9 October 2014
WO/2014/161036, Stimulus responsive substrates, University of South Australia, 9 October 2014
WO/2014/161031, Nanoparticles for drug delivery comprising albumin having a polymer chain coupled thereto, Newsouth Innovations, 9 October 2014
WO/2014/153624, Antibacterial compounds, University of Sydney, 2 October 2014
WO/2014/153620, Method for generating mature β-like cells, University of Western Australia, 2 October 2014
WO/2014/153614, Improved methods for osteoarthritis therapy, Cell-Innovations, 2 October 2014
WO/2014/140797, MicroRNA-based approach to treating malignant pleural mesothelioma, Asbestos Diseases Research Foundation, 18 September 2014
WO/2014/138824, Immune modulation, Sementis, 18 September 2014
WO/2014/138823, Compounds and uses thereof in the treatment/prevention of Gram-negative bacterial infections, Griffith University, 18 September 2014
WO/2014/138821, Improved air purifying apparatus, method & use of chemical substance, Air Sanz, 18 September 2014
WO/2014/138819, Agents that neutralize Il-3 signaling and uses thereof, CSL Ltd, 18 September 2014
WO/2014/138814, S-enantiomerically enriched compositions of beta blockers for treating Amyotrophic Lateral Sclerosis, Andrew Coats with Stefan Anker (Germany) and Jochen Springer (Germany), 18 September 2014
WO/2014/138812, Salts, co-crystals, and polymorphs of an anxiolytic compound, Bionomics, 18 September 2014
WO/2014/138806, Oxprenolol compositions for treating cancer, Andrew Coats with Stefan Anker (Germany) and Jochen Springer (Germany), 18 September 2014
WO/2014/138805, Anti Il-3r alpha agents and uses thereof, CSL Ltd, 18 September 2014
WO/2014/138802, Canrenoate compositions for treating cancer, Andrew Coats with Stefan Anker (Germany) and Jochen Springer (Germany), 18 September 2014
WO/2014/138796, Dosage regimen for therapeutic method, Madeleine Pharmaceuticals, 18 September 2014
WO/2014/138793, A method of isolating cells for therapy and prophylaxis, University of Queensland, 18 September 2014
WO/2014/138791, Transgenic non-human organisms with non-functional TSPO genes, Australian Nuclear Science and Technology Organisation, 18 September 2014
WO/2014/138772, A crystalline form of an anxiolytic compound, Bionomics, 18 September 2014
WO/2014/134689, Polymer conjugate for delivery of a bioactive agent, Polyactiva, 12 September 2014
WO/2014/132100, Mobilizing agents and uses therefor, Mater Medical Research Institute, 4 September 2014
WO/2014/128628, Cytoplasmic expression of Fab proteins, Affinity Biosciences, 28 August 2014
WO/2014/128465, 2-(Hetero)Aryl-Benzimidazole and Imidazopyridine derivatives as inhibitors of asparagine emethyl transferase, Cancer Therapeutics CRC, 28 August 2014
WO/2014/127418, Conjugate compound and uses of same, University of Queensland, 28 August 2014
WO/2014/124487, Ligand binding molecules and uses thereof, Vegenics, 21 August 2014
WO/2014/122638, Thalidomide and thalidomide analogues for the stimulation of stem cell factor, Patrick Prendergast, 14 August 2014
WO/2014/121343, Methods of treating microbial infections, including mastitis, Luoda Pharma, 14 August 2014
WO/2014/121342, Methods of treating topical microbial infections, Luoda Pharma, 14 August 2014
WO/2014/121325, Il-11r binding proteins and uses thereof, CSL Ltd, 14 August 2014
WO/2014/117220, Anti-CD83 antibodies and use thereof, Transbio with the University of Queensland and the University of California (US), 7 August 2014
WO/2014/117218, Slow release endodontic paste, Matthew Athanassiadis, 7 August 2014
WO/2014/113839, A method for improving the wellbeing of an animal using a composition including Vitamin K, Hubertus Regtop, 31 July 2014
WO/2014/113836, Treatment methods, Marinova, 31 July 2014
WO/2014/107763, Age-Related Macular Degeneration treatment, Benitec Biopharma, 17 July 2014
WO/2014/100857, Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy, Cell Ideas, 3 July 2014
WO/2014/100852, Inhibition of cancer growth and metastasis, Royal Melbourne Institute of Technology, 3 July 2014
WO/2014/100851, Improved antimicrobial compositions, Novapharm Research, 3 July 2014
WO/2014/094043, Methods of generating cells with multilineage potential, Newsouth Innovations, 26 June 2014
WO/2014/094041, Treatment of diseases involving mucin, Pitney Pharmaceuticals, 26 June 2014
WO/2014/094032, Polymorph, Oncology Research International, 26 June 2014
WO/2014/089620, Compositions and method for maintaining/improving cognitive function, Blackmores, 19 June 2014
WO/2014/089610, Scalable three-dimensional elastic construct manufacturing, Elastagen, 19 June 2014
WO/2014/085866, Use of miRNA antagonists for immune system modulation, treatment of bacterial infections and treatment of airways diseases, Newcastle Innovation, 12 June 2014
WO/2014/085851, Uses of Bacopa Monnieri extract, Soho Flordis International, 12 June 2014
WO/2014/085613, Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD2 inhibition, McCord Research (US) with Tom Karagiannis, 5 June 2014
WO/2014/082132, Microparticles comprising a probiotic, cross-linkable reagent, a denatured protein, polyol plasticiser and trehalose, Progel, 5 June 2014
WO/2014/082131, A microparticle composition comprising a probiotic, cross-linkable reagent and an emulsion containing a hydrophobic active, Progel, 5 June 2014
WO/2014/078912, Coating composition, Progel, 30 May 2014
WO/2014/078911, Compositions for the restoration of a fecal microbiota and methods for making and using them, Thomas Borody, 30 May 2014
WO/2014/078900, Anti-pathogenic methods, Hexima, 30 May 2014
WO/2014/078896, Complex-formation-modulating agents and uses therefor, Queensland University of Technology, 30 May 2014
WO/2014/078895, Omega-3 analogues, University of Sydney, 30 May 2014
WO/2014/078889, Improved inhibitors of GRB7, Monash University, 30 May 2014
WO/2014/075146, Macrocyclic compounds and uses thereof, Adelaide Research & Innovation, 22 May 2014
WO/2014/075137, Peptides incorporating amino-substituted lactams for treatment of retinopathy, Biodiem, 22 May 2014
WO/2014/075135, Transmucosal delivery of tocotrienol, Gordagen Pharmaceuticals, 22 May 2014
WO/2014/075125, Soluble mediator, Walter and Eliza Hall Institute of Medical Research, 22 May 2014
WO/2014/075124, Methods and compositions for the treatment and/or prevention of bowel disorders, Victoria University, 22 May 2014
WO/2014/072766, Herbal compositions for the prevention or treatment of urinary incontinence and overactive bladder, Tracey Seipel, 15 May 2014
WO/2014/072493, Pharmaceutical combination comprising a B-RAF inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases, Novartis with the Kolling Institute, 15 May 2014
WO/2014/071457, Dual action nitric oxide donors and their use as antimicrobial agents, Newsouth Innovations, 15 May 2014
WO/2014/071449, Neuroactive steroids and their use to facilitate neuroprotection, Goodchild Investments, 15 May 2014
WO/2014/071438, Modified polyphenols and modified polyphenol compositions, Cellarouge, 15 May 2014
WO/2014/066951, Dental compositions, Ozdent, 8 May 2014
WO/2014/066945, Genetically-modified probiotic for treatment of phenylketonuria, The Sydney Children's Hospital Network, 8 May 2014
WO/2014/066943, Reconstituted HDL formulation, CSL Ltd, 8 May 2014
WO/2014/066939, Novel immunotherapeutic molecules and uses thereof, Monash University, 8 May 2014
WO/2014/063205, Use of endocytosis inhibitors and antibodies for cancer therapy, University of Queensland, 1 May 2014
WO/2014/063199, Organic compounds, Akaal Pharma, 1 May 2014
WO/2014/063198, A radioisotope concentrator, Cyclopharm, 1 May 2014
WO/2014/063193, Substituted sulfone-containing tricyclic compounds and uses thereof, Walter and Eliza Hall Institute of Medical Research, 1 May 2014
WO/2014/063190, Method for reducing triglycerides, Deakin University, 1 May 2014
WO/2014/063189, Methods and products for preventing and/or treating a stress induced cardiomyopathy, Adelaide Research & Innovation, 1 May 2014
WO/2014/059489, Improved human herpesvirus immunotherapy, Queensland Institute of Medical Research, 24 April 2014
WO/2014/059484, Cancer therapy using miRNAs, University of Western Australia, 24 April 2014
WO/2014/059429, Small molecules inhibiting oncoprotein Myc, Health Research (US), Panacela Labs (US), Children's Cancer Institute, 17 April 2014
WO/2014/056039, Antimicrobial peptides modified for mammalian cell recognition and/or adhesion, Newsouth Innovations, 17 April 2014
WO/2014/056038, Novel flavonoid compounds and uses thereof, Armaron Bio, 17 April 2014
WO/2014/056026, Improved process for purifying growth factors from milk and products thereof, Murray Goulburn Co-Operative Co., 17 April 2014
WO/2014/056025, Improved process for purifying lactoferrin from milk and products thereof, Murray Goulburn Co-Operative Co., 17 April 2014
WO/2014/053014, Modulation of RNA activity and vascular permeability, Centenary Institute of Cancer Medicine and Cell Biology, 10 April 2014
WO/2014/052640, Novel AMPK agonist compositions and methods of use, Paul Plante (US) with Barbara Badenoch-Jones and Sebastian Marcuccio, 3 April 2014
WO/2014/049556, Neurotrophin-tyrosine kinase receptor signaling, University of Queensland, 3 April 2014
WO/2014/045283, Restoration of the CFTR function by splicing modulation, Hebrew University of Jerusalem (Israel) with University of Western Australia, 27 March 2014
WO/2014/043743, Viscous haemostatic compostions and method of treatment, Eupharma, 27 March 2014
WO/2014/043576, Method of treatment or prophylaxis of infections of the eye, Starpharma, 20 March 2014
WO/2014/041425, Daptomycin formulations and uses thereof, Hospira Australia, 20 March 2014
WO/2014/041349, Tetrahydropyran-4-Ylethylamino- or Tetrahydropyranyl-4-Ethyloxy-Pyrimidines or -Pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors, Cancer Therapeutics CRC, 20 March 2014
WO/2014/040143, Method of treating cancer, Bruce Gray, 20 March 2014
WO/2014/036608, Methods and products for preventing and/or treating metastatic cancer, Adelaide Research & Innovation, 13 March 2014
WO/2014/036603, Uses of (-)-perhexiline, Adelaide Research & Innovation, 13 March 2014
WO/2014/036595, Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth, Bionomics, 13 March 2014
WO/2014/032099, Composition and method for bone growth, The Sydney Children's Hospitals Network, 6 March 2014
WO/2014/032082, Modified human rotaviruses and uses therefor, Murdoch Childrens Research Institute, 6 March 2014
WO/2014/028968, Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof, Peter MacCallum Cancer Institute, 27 February 2014
WO/2014/027199, FAK and FLT3 inhibitors, Cancer Therapeutics CRC, 20 February 2014
WO/2014/026243, VEGFR3 inhibitors, Cancer Therapeutics CRC, 20 February 2014
WO/2014/026242, VRGFR3 inhibitors, Cancer Therapeutics CRC, 20 February 2014
WO/2014/022886, A method, use, and dietary supplement composition for at least treating an atopic or non-atopic disorder in a patient, Karen Fischer, 13 February 2014
WO/2014/022879, Compounds for the treatment of mTOR pathway related diseases, Pitney Pharmaceuticals, 13 February 2014
WO/2014/019025, EpCAM aptamer for detection of cancer stem cells, Deakin University, 6 February 2014
WO/2014/019024, CD133 aptamers for detection of cancer stem cells, Deakin University, 6 February 2014
WO/2014/015388, A method for polishing albumin, CSL Ltd, 30 January 2014
WO/2014/015367, Polymers for siRNA delivery, University of Queensland, 30 January 2014
WO/2014/012147, Method of diagnosis and treatment, Latrobe University, 23 January 2014
WO/2014/008542, Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders, Brien Holden Vision Institute, 16 January 2014
WO/2014/008263, Paramyxovirus and methods of use, Henry M. Jackson Foundation for the Advancement of Military Medicine with CSIRO and the Queensland Department of Agriculture and Fisheries, 9 January 2014
WO/2014/007821, Compositions and methods for detecting anastomosis leakage, Empire Technology Development, 9 January 2014
WO/2014/005186, Methods for inhibiting neuron apoptosis and necrosis, Newsouth Innovations, 9 January 2014
WO/2014/005183, Treatment of inflammatory skin disorders, University of Sydney, 9 January 2014
WO/2014/005182, Phosphoinositide 3-Kinase (Pi3K) inhibitors, Monash University, 9 January 2014
WO/2014/000058, Method of treating glucose metabolism disorders, Garvan Institute of Medical Research, 3 January 2014
WO/2014/000042, Compositions and methods for modifying TGF-Β family ligands, Hudson Institute of Medical Research, 3 January 2014
WO/2014/000033, Polymer-NSAID conjugate, Polyactiva, 3 January 2014
WO/2014/000032, Phenyl amino pyrimidine bicyclic compounds and uses thereof, YM Biosciences Australia, 3 January 2014
WO/2014/000029, Compositions and methods for reducing frequency and/or severity of headache, Rusty Property Holdings, 3 January 2014
WO/2014/000027, Prevention and treatment of haematological conditions, University of Technology, Sydney, 3 January 2014
WO/2014/000026, Recombinant viral vectors and uses therefor, University of Canberra, 3 January 2014

New Zealand applications

Here are the 41 PCT patent applications relevant to New Zealand's Life Sciences sector that published in 2014, for a publication rate of 0.8 applications per week:

WO/2014/209136, Anti-viral compound and composition, Forest Herbs Research, 31 December 2014
WO/2014/200363, Sphingoglycolipid analogues, Victoria Link, 18 December 2014
WO/2014/193248, Beta-casein A2 and prevention of inflammation of the bowel, The A2 Milk Company, 4 December 2014
WO/2014/189392, Methods and compositions for the disruption of biofilms and treatment of disorders characterized by the presence of biofilms, Breathe Easy, 27 November 2014
WO/2014/189386, Method for supervising consumption of a medical food comprising Eicosapentaenoic Acid for prevention and/or management of a disease or condition, Photonz Corporation, 27 November 2014
WO/2014/185792, Oral healthcare product, Alequident, 20 November 2014
WO/2014/171842, Biocompatible encapsulation system, Living Cell Technologies, 23 October 2014
WO/2014/167530, Cannabinoid compounds, Matthew Bowden and James Williamson, 16 October 2014
WO/2014/163513, Therapeutic compositions and uses thereof, Manuka Health New Zealand, 9 October 2014
WO/2014/163512, Therapeutic compositions comprising extracts of propolis and uses thereof, Manuka Health New Zealand, 9 October 2014
WO/2014/158033, Stabilized Vitamin D formulations, API Consumer Brands, 2 October 2014
WO/2014/153514, Contraceptive vaccines for mammals, Patrick Casey and Irwin Liu, 25 September 2014
WO/2014/142675, Nanofibre and bioactive compositions and related methods, Active Fibres, 18 September 2014
WO/2014/141223, Chewable formulation, Argenta, 18 September 2014
WO/2014/137229, Neural regeneration peptides and uses therefor, CuroNZ, 12 September 2014
WO/2014/132227, Transdermal formulations, Argenta, 4 September 2014
WO/2014/129914, Methods of treatment, Auckland Uniservices, 28 August 2014
WO/2014/120021, A combination medicament comprising phenylephrine and paracetamol, AFT Pharmaceuticals, 7 August 2014
WO/2014/116121, Assembly of micelle aggregates of surfactant micelles and silver nanoparticles and use as antibacterial agent, Otago Innovation, 31 July 2014
WO/2014/098624, Veterinary injectable formulations, Alleva Animal Health, 26 June 2014
WO/2014/098623, Injectable eprinomectin formulation and anthelmintic use thereof, Alleva Animal Health, 26 June 2014
WO/2014/098619, Transdermal parasiticidal formulations, Donaghys, 26 June 2014
WO/2014/088432, Conjugate compounds, Callaghan Innovation, 12 June 2014
WO/2014/085480, Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid, Neuren Pharmaceuticals, 5 June 2014
WO/2014/084744, Saccharide dendritic cluster compounds as inhibitors of BACE-1, The University Of Liverpool (UK) with Victoria Link, 5 June 2014
WO/2014/073989, Salt and polymorphic forms of (3R,4S)-L-((4-Amino-5H-Pyrrolo[3,2-D]Pyrimidin-7-Yl)Methyl)-4(Methylthiomethyl)Pyrodin-3-Ol(Mtdia), Victoria Link, 15 May 2014
WO/2014/057414, Ketamine derivatives, Auckland Uniservices, 17 April 2014
WO/2014/051442, Veterinary pharmaceutical formulations and methods, Nexan Corporation, 3 April 2014
WO/2014/051440, Ectoparasitic treatment method and composition, Bayer New Zealand, 3 April 2014
WO/2014/043046, Treatment and prevention of P. Aeruginosa infections using coformycin analogs, Albert Einstein College of Medicine of Yeshiva University (US) with Callaghan Innovation, 20 March 2014
WO/2014/038963, Dendrimer scaffolds for pharmaceutical use, Victoria Link, 13 March 2014
WO/2014/038962, Methods and uses of an extract from olive leaf in management of Type 2 Diabetes, Apimed Medical Honey, 13 March 2014
WO/2014/030142, Nitroimidazole compounds and their use in cancer therapy, Auckland Uniservices, 27 February 2014
WO/2014/027899, NTproCNP as a biomarker of vascular disorders and pregnancy complication, Otago Innovation, 20 February 2014
WO/2014/025842, Treatment of Helicobacter Pylori infections, Albert Einstein College of Medicine of Yeshiva University (US) with Callaghan Innovation, 13 February 2014
WO/2014/017928, Organic compounds, Callaghan Innovation, 30 January 2014
WO/2014/017927, Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury, CuroNZ, 30 January 2014
WO/2014/014364, Injectable antibiotic formulations and their methods of use, Bayer New Zealand, 23 January 2014
WO/2014/014363, Injectable antibiotic formulations and their methods of use, Bayer New Zealand, 23 January 2014
WO/2014/007661, Methods for determining personalized treatment compositions for prostate cancer and breast cancer, Caldera Health, 9 January 2014.
WO/2014/007650, Compounds and methods for selective imaging and/or ablation, Auckland Uniservices, 9 January 2014